Ionis Pharmaceuticals (IONS) –
-
Ionis Publishes 2023 Corporate Responsibility Report
-
Ionis to hold first quarter 2024 financial results webcast
-
Form 4 IONIS PHARMACEUTICALS For: Apr 15 Filed by: Baroldi Joseph
-
Form 4 IONIS PHARMACEUTICALS For: Apr 15 Filed by: Birchler Brian
-
Form 144 IONIS PHARMACEUTICALS Filed by: Baroldi Joseph
-
Form 144 IONIS PHARMACEUTICALS Filed by: Birchler Brian
-
Wolfe Research Upgrades Ionis Pharmaceuticals (IONS) to Outperform on Catalysts and Revenue Potential
-
Form 8-K IONIS PHARMACEUTICALS For: Apr 07
-
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
-
Ionis to present at upcoming investor conferences
-
Ionis to hold olezarsen Phase 3 data webcast
-
Ionis Pharmaceuticals (IONS) to Present Positive Phase 3 Balance Data
-
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
-
Form 4 IONIS PHARMACEUTICALS For: Feb 26 Filed by: Jenne Kyle
-
Form 3 IONIS PHARMACEUTICALS For: Feb 26 Filed by: Jenne Kyle
-
Laidlaw Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) Reports Positive Results from Phase 2 Study of ION224
-
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
-
Biogen (BIIB) Reports New Biomarker Data Supporting the Potential Benefit of SPINRAZA
-
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
-
Ionis Pharmaceuticals (IONS) PT Raised to $72 at Oppenheimer
-
Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: Monia Brett P
-
Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: Swayze Eric
-
Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: Geary Richard S
-
Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: Birchler Brian
-
Form 4 IONIS PHARMACEUTICALS For: Feb 29 Filed by: BENNETT C FRANK
-
Form 8-K IONIS PHARMACEUTICALS For: Feb 28
-
Ionis Pharmaceuticals (IONS) Appoints Kyle Jenne as Chief Global Product Strategy Officer
-
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
-
Ionis to present at upcoming investor conferences
-
Ionis Pharmaceuticals (IONS) PT Raised to $65 at Oppenheimer
-
Form 10-K IONIS PHARMACEUTICALS For: Dec 31
-
Form 8-K IONIS PHARMACEUTICALS For: Feb 21
-
Ionis Pharmaceuticals (IONS) Tops Q4 EPS by 76c, provides guidance
-
Ionis reports fourth quarter and full year 2023 financial results
-
Form 144/A IONIS PHARMACEUTICALS Filed by: Monia Brett P
-
Form 4 IONIS PHARMACEUTICALS For: Feb 16 Filed by: Monia Brett P
-
Form 144 IONIS PHARMACEUTICALS Filed by: Monia Brett P
-
Wolfe Research begins coverage on biotech, names Alpine Immune Sciences as Top Pick
-
Ionis Pharmaceuticals (IONS) Granted FDA Orphan Drug designation for Olezarsen
-
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
-
Form SC 13G IONIS PHARMACEUTICALS Filed by: T. Rowe Price Investment Management, Inc.
-
Form SC 13G/A IONIS PHARMACEUTICALS Filed by: VANGUARD GROUP INC
-
Form SC 13G/A IONIS PHARMACEUTICALS Filed by: BB BIOTECH AG
-
Form SC 13G/A IONIS PHARMACEUTICALS Filed by: FMR LLC
-
Ionis Pharmaceuticals (IONS) Granted FDA Fast Track Designation for Eplontersen
-
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
-
Ionis to hold fourth quarter and full year 2023 financial results webcast
-
Form 4 IONIS PHARMACEUTICALS For: Feb 01 Filed by: O'NEIL PATRICK R.
-
Form 4 IONIS PHARMACEUTICALS For: Jan 31 Filed by: Swayze Eric
Back to IONS Stock Lookup
